Pathstone Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Pathstone Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$5.5M	Buy	15,820 +8,726	+123%	+$3.05M	0.04%	255
2023 Q2	$2.55M	Sell	7,094 -81	-1%	-$27.3K	0.04%	275
2023 Q1	$2.15M	Sell	7,175 -19,953	-74%	-$5.98M	0.03%	278
2022 Q4	$6.93M	Buy	27,128 +5,438	+25%	+$1.66M	0.06%	223
2022 Q3	$6.29M	Buy	21,690 +17,219	+385%	+$4.95M	0.06%	196
2022 Q2	$1.26M	Buy	4,471 +506	+13%	+$135K	0.03%	297
2022 Q1	$1.04M	Sell	3,965 -518	-12%	-$123K	0.02%	319
2021 Q4	$985K	Buy	4,483 +1,861	+71%	+$362K	0.02%	345
2021 Q3	$475K	Buy	2,622 +333	+15%	+$65K	0.01%	537
2021 Q2	$462K	Buy	2,289 +313	+16%	+$65.5K	0.01%	496
2021 Q1	$425K	Buy	1,976 +1,375	+229%	+$302K	0.01%	382
2020 Q4	$142K	Buy	601 +91	+18%	+$20.9K	0.01%	327
2020 Q3	$139K	Hold	510	–	–	0.02%	235
2020 Q2	$148K	Hold	510	–	–	0.02%	186
2020 Q1	$122K	Buy	510 +261	+105%	+$59.9K	0.02%	207
2019 Q4	$545K	Hold	249	–	–	0.01%	281
2019 Q3	$42K	Hold	249	–	–	0.01%	299
2019 Q2	$46K	Hold	249	–	–	0.01%	339
2019 Q1	$46K	Buy	+249	New	+$46K	0.01%	317
2017 Q2	–	Sell	-38	Closed	-$4K	–	644
2017 Q1	$4K	Buy	+38	New	+$3.35K	﹤0.01%	335
2016 Q4	–	Sell	-30	Closed	-$3K	–	205
2016 Q3	$3K	Sell	30 -27	-47%	-$2.55K	﹤0.01%	181
2016 Q2	$5K	Hold	57	–	–	﹤0.01%	182
2016 Q1	$4K	Buy	+57	New	+$5.16K	0.01%	152

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Family Office's VRTX Position: Q3 2023 in Review

Pathstone Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 123% in Q3 2023, buying an estimated $3.05M and bringing the position to 15,820 shares worth $5.5M. The position accounts for 0.04% of the portfolio, ranked #255.

Pathstone Family Office first reported a position in VRTX in Q1 2016 and has held it in 23 quarters since. The position peaked at $6.93M in Q4 2022. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Pathstone Family Office held 15,820 shares of Vertex Pharmaceuticals worth $5.5M as of Q3 2023.
Pathstone Family Office bought 8,726 Vertex Pharmaceuticals shares in Q3 2023, an estimated $3.05M.
Vertex Pharmaceuticals made up 0.04% of Pathstone Family Office's portfolio in Q3 2023, its #255 holding.
Pathstone Family Office first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 23 quarters since.
Pathstone Family Office's Vertex Pharmaceuticals position peaked at $6.93M in Q4 2022.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.